Literature DB >> 10475386

Thoracic Surgery Directors Association Award. Angiogenesis in transmyocardial revascularization: comparison of laser versus mechanical punctures.

V F Chu1, A Giaid, J Q Kuang, A N McGinn, C M Li, M P Pelletier, R C Chiu.   

Abstract

BACKGROUND: Transmyocardial laser revascularization (TMLR), which has been shown to reduce angina in clinical trials, was originally based on the belief that laser channels are unique and can remain patent. An increasing body of evidence indicates otherwise, and transmyocardial revascularization (TMR) angiogenesis is currently thought to be induced by nonspecific inflammatory response to tissue injuries. We tested the hypothesis that mechanical transmyocardial revascularization (TMMR) may induce angiogenic responses similar to that seen with lasers.
METHODS: Ameroid constrictors were implanted around proximal circumflex arteries of porcine hearts. Six weeks later, they were randomly assigned (n = 5 each) to receive 10 transmural channels in the ischemic zone by a carbon dioxide laser (group I) or by a needle (group II). A third group (group III) had 30 needle channels in the same area, while a control group (group IV) received no TMR. The hearts were harvested 1 week later, and, using immunohistochemistry, vascular endothelial growth factor (VEGF) expression was studied and quantified by computerized morphometric analysis. Densities of vascular structures positively stained for VEGF per high-power field (HPF) were also compared.
RESULTS: Virtually no TMR channels remained patent histologically. Group III had a significant higher level of total VEGF expression (14.18+/-0.78 mm2) compared with group I (7.07+/-2.06 mm2, p < 0.001) and group II (4.74+/-3.35 mm2, p < 0.001). Vascular density was significantly elevated in all treatment groups compared with the control (group I, 7.7+/-0.8/HPF vs group II, 4.5+/-2.3/HPF vs group III, 8.1+/-0.6/HPF vs group IV, 1.1+/-0.5/HPF).
CONCLUSIONS: In view of the significant cost implications, our findings that needle punctures may also induce angiogenic response comparable with that with laser suggest that it is justifiable and desirable to include a TMMR arm for comparison with TMLR in future clinical trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10475386     DOI: 10.1016/s0003-4975(99)00680-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

Review 1.  Epicardial gene therapy and laser revascularization.

Authors:  J F Symes
Journal:  Curr Cardiol Rep       Date:  1999-11       Impact factor: 2.931

2.  Method for inducing the growth of new arteries in the myocardium.

Authors:  Yasuharu Noishiki
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2006-08

3.  Transmyocardial revascularization ameliorates ischemia by attenuating paradoxical catecholamine-induced vasoconstriction.

Authors:  D Elizabeth Le; Eric R Powers; Jian-Ping Bin; Howard Leong-Poi; N Craig Goodman; Sanjiv Kaul
Journal:  J Nucl Cardiol       Date:  2007-04       Impact factor: 5.952

4.  Degradable PLGA scaffolds with basic fibroblast growth factor: experimental studies in myocardial revascularization.

Authors:  Ying Wang; Xiao-Cheng Liu; Jian Zhao; Xiang-Rong Kong; Rong-Fang Shi; Xiao-Bin Zhao; Cun-Xian Song; Tian-Jun Liu; Feng Lu
Journal:  Tex Heart Inst J       Date:  2009

Review 5.  Transmyocardial laser revascularization.

Authors:  Keith A Horvath
Journal:  J Card Surg       Date:  2008 May-Jun       Impact factor: 1.620

Review 6.  Tissue Engineering of the Microvasculature.

Authors:  Joe Tien
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.